A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway

BACKGROUND: Anti-angiogenic therapy has been widely applied to the clinical treatment of malignant tumors. However, the efficacy of such treatments has been called into question, especially in triple-negative breast cancer (TNBC). Bevacizumab, the first anti-angiogenic agent approved by FDA, actuall...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Wei, Zhao, Huijie, Wang, Fengxian, Wang, Yiyun, He, Yuan, Wang, Tong, Zhang, Kunchi, Yang, Hao, Zhou, Zhaoli, Shi, Haibin, Wang, Jin, Huang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802198/
https://www.ncbi.nlm.nih.gov/pubmed/33436039
http://dx.doi.org/10.1186/s13046-020-01800-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802198/
https://www.ncbi.nlm.nih.gov/pubmed/33436039
http://dx.doi.org/10.1186/s13046-020-01800-x

Ejemplares similares